<DOC>
	<DOCNO>NCT02532452</DOCNO>
	<brief_summary>The purpose study demonstrate viral specific T-cells ( type white blood cell ) generate unrelated donor give safely patient viral infection .</brief_summary>
	<brief_title>Third Party Anti-Viral Cytotoxic T-Cells</brief_title>
	<detailed_description>Viral reactivation infection major cause morbidity immunocompromised patient ( include HSCT recipient ) . In study draw blood unrelated ( third party ) donor use blood generate cytotoxic T-lymphocytes ( CTLs ) specificity EBV , CMV adenovirus . The CTL 's frozen infuse freshly infuse immunocompromised child specific viral infection ( EBV , CMV adenovirus ) . Cells select infusion base recipient 's HLA type viral specificity cell .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Immunocompromised patient evidence viral infection reactivation Age &gt; 1 day Recipients stem cell transplant must great 28 day stem cell infusion Clinical status must allow taper steroid &lt; 0.5mg/kg prednisone steroid equivalent Must able receive CTL infusion CCHMC Informed consent obtain PI subinvestigator CCHMC Active acute GVHD grade IIIV Uncontrolled bacterial fungal infection Uncontrolled relapse malignancy Infusion ATG alemtuzumab within 2 week CTL infusion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Epstein-Barr Virus ( EBV )</keyword>
	<keyword>Adenovirus ( ADV )</keyword>
	<keyword>Cytomegalovirus ( CMV )</keyword>
	<keyword>T-Cells</keyword>
	<keyword>Donor</keyword>
</DOC>